Mr. Chand Jagpal reports

ALBERT LABS MANAGEMENT AND BOARD OF DIRECTOR ANNOUNCEMENT

Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors.

The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company.

Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.

About Albert Labs International Corp.

Albert Labs is a pharmaceutical drug development company, focused on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverages advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast-track clinical pathway focusing on real-world evidence (RWE). RWE studies are an increasingly recognized clinical route, heavily used in oncology and, recently, in the successful development of COVID-19 vaccines.

We seek Safe Harbor.